Cyanotech stock analysis
Want to see CYAN full AI Analyst Report?
Cyanotech (CYAN) Stock Price & Analysis
CYAN Stock Chart & Stats
- Day’s Range
- $0.55 - $0.57
- 52-Week Range
- $0.23 - $0.78
- Previous Close
- $0.59
- Volume
- N/A
- Average Volume (3M)
- 7,005
- Market Cap
- $4.07M
- Enterprise Value
- $13.15M
- Total Cash (Recent Filing)
- $770.00K
- Total Debt (Recent Filing)
- $11.14M
- Price to Earnings (P/E)
- 5.0
- Beta
- 0.44
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Stabilization
Revenue growth has returned after the 2024 trough, indicating that demand for Cyanotech’s products has stabilized and modestly expanded. Continued top-line improvement would provide a foundation for better operating leverage and support the company’s efforts to convert improving sales into sustainable profitability.
Margin And EBITDA Improvement
The recovery in gross margin and positive EBITDA show meaningful operational progress from the 2024 low point. Better product economics can improve the company’s ability to absorb fixed costs, retain more revenue as operating cash, and move closer to consistent profitability over the next several quarters.
Diversified Product Model
Cyanotech serves customers through both bulk ingredient sales and branded finished products, reducing reliance on a single commercial route. Its focus on astaxanthin and spirulina also gives the business exposure to nutritional supplement and health-and-wellness applications across business and consumer markets.
Bears Say
Persistent Net Losses
Despite substantial improvement from the 2024 loss, Cyanotech has not yet reached net profitability. Continued losses indicate that operating improvements remain insufficient to cover the full cost base, limiting retained capital and making sustained earnings generation an unresolved fundamental challenge.
Rising Leverage
The sharp increase in debt relative to equity has reduced financial flexibility and increased the importance of stable operating performance. A shrinking equity base leaves less capacity to absorb setbacks, while elevated leverage can constrain future investment and place greater pressure on cash generation.
Fragile Cash Generation
Cash generation has only recently turned slightly positive and remains small relative to the company’s earnings profile. This limited internal funding capacity could restrict reinvestment or debt reduction, while any renewed operating weakness could quickly return cash flow to negative territory.
Cyanotech News
CYAN FAQ
What was Cyanotech’s price range in the past 12 months?
What is Cyanotech’s market cap?
When is Cyanotech’s upcoming earnings report date?
How were Cyanotech’s earnings last quarter?
Is Cyanotech overvalued?
Does Cyanotech pay dividends?
What is Cyanotech’s EPS estimate?
How many shares outstanding does Cyanotech have?
What happened to Cyanotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cyanotech?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cyanotech
Established in 1983 and headquartered in Kailua-Kona, Hawaii, Cyanotech Corporation specializes in the global cultivation, processing, and distribution of natural products derived from microalgae. Its key product offerings include BioAstin Hawaiian Astaxanthin, a powerful dietary antioxidant acclaimed for promoting skin health and supporting eye, joint, and immune system functions; it is utilized as both a dietary supplement and an ingredient. Another significant product is Hawaiian Spirulina Pacifica, a highly nutritious dietary supplement formulated to enhance energy levels, bolster the immune system, provide cardiovascular benefits, and deliver a rich source of antioxidant carotenoids. Beyond its product lines, Cyanotech also offers contract extraction services. The company reaches its customers through a diverse array of sales channels, encompassing third-party distributors, retailers, and online platforms, as well as direct sales to consumers. Additionally, it supplies products in bulk to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries.
- Sector
- Consumerdefensive
- Industry
- Packaged Foods
- CEO
- Matthew Keith Custer
- Employees
- 83
- Website
- www.cyanotech.com
- Address
- 73-4460 Queen Kaahumanu Highway, Kailua-Kona, HI, 96740, US
Cyanotech (CYAN) Earnings & Revenues
CYAN Earnings Call
Earnings Call SentimentNeutral
The earnings call presented a mixed picture with notable growth in contract extraction revenue and improved inventory and capital metrics. However, significant declines in net sales, gross profit margin, and an increased net loss, largely due to inventory challenges, highlight ongoing challenges.
View all CYAN earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 4 | 5 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 11 | 0 | 1 |









